- Home
- UFCS vs NRIX Comparison
UFCS vs NRIX Comparison
Compare UFCS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- NRIX
- Stock Information
- Founded
- UFCS 1946
- NRIX 2009
- Country
- UFCS United States
- NRIX United States
- Employees
- UFCS N/A
- NRIX N/A
- Industry
- UFCS Property-Casualty Insurers
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- NRIX Health Care
- Exchange
- UFCS Nasdaq
- NRIX Nasdaq
- Market Cap
- UFCS 922.3M
- NRIX 750.4M
- IPO Year
- UFCS N/A
- NRIX 2020
- Fundamental
- Price
- UFCS $37.44
- NRIX $16.75
- Analyst Decision
- UFCS Buy
- NRIX Strong Buy
- Analyst Count
- UFCS 2
- NRIX 14
- Target Price
- UFCS $33.00
- NRIX $26.50
- AVG Volume (30 Days)
- UFCS 125.9K
- NRIX 1.7M
- Earning Date
- UFCS 11-04-2025
- NRIX 10-09-2025
- Dividend Yield
- UFCS 1.72%
- NRIX N/A
- EPS Growth
- UFCS 118.04
- NRIX N/A
- EPS
- UFCS 4.24
- NRIX N/A
- Revenue
- UFCS $1,353,781,000.00
- NRIX $83,687,000.00
- Revenue This Year
- UFCS $12.34
- NRIX $58.48
- Revenue Next Year
- UFCS $14.56
- NRIX N/A
- P/E Ratio
- UFCS $8.80
- NRIX N/A
- Revenue Growth
- UFCS 12.12
- NRIX 48.32
- 52 Week Low
- UFCS $24.11
- NRIX $8.18
- 52 Week High
- UFCS $37.48
- NRIX $23.00
- Technical
- Relative Strength Index (RSI)
- UFCS 67.91
- NRIX 78.50
- Support Level
- UFCS $36.03
- NRIX $12.43
- Resistance Level
- UFCS $37.35
- NRIX $17.65
- Average True Range (ATR)
- UFCS 1.10
- NRIX 1.00
- MACD
- UFCS 0.02
- NRIX 0.42
- Stochastic Oscillator
- UFCS 90.11
- NRIX 88.13
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.